当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Management and Outcomes in Metaplastic Breast Cancer.

Management and Outcomes in Metaplastic Breast Cancer.

Abstract：

:Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its management a challenge. Thus, the scope of the present review is to discuss the current therapeutic strategies for MBC in clinical practice and the corresponding outcomes and to suggest possible directions for future research. Potential novel targeted therapies could provide a hope for better outcomes but limited data are available owing to the rarity of MBC. As knowledge accumulates on the pathogenesis and genetic characteristics of MBC, emphasis should be given to the implementation of more targeted treatments, which will allow more efficient and individualized management of the disease.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Tzanninis IG,Kotteas EA,Ntanasis-Stathopoulos I,Kontogianni P,Fotopoulos G

doi

10.1016/j.clbc.2016.06.002

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

437-443

issue

6

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(16)30144-6

journal_volume

16

pub_type

杂志文章,评审

相关文献

Clinical Breast Cancer文献大全
  • Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis.

    abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.03.007

    authors： Dianatinasab M,Rezaian M,HaghighatNezad E,Bagheri-Hosseinabadi Z,Amanat S,Rezaeian S,Masoudi A,Ghiasvand R

    更新日期：2020-08-01 00:00:00

  • Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?

    abstract：INTRODUCTION:The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our aim was to assess the outcomes of, and treatments administered to, women with small (≤...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.12.012

    authors： Tognela A,Beith J,Kiely B,Bastick P,Lynch J,Descallar J,Mok K

    更新日期：2015-08-01 00:00:00

  • Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.

    abstract：BACKGROUND:The prognostic/predictive value of aberrant MYC gene copies and protein expression is not clear in breast cancer. PATIENTS AND METHODS:Early breast cancer patients were treated with anthracycline-containing chemotherapy within 2 randomized adjuvant trials. MYC gene and centromere-8 status, as well as Myc pr...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clbc.2017.07.004

    authors： Batistatou A,Kotoula V,Bobos M,Kouvatseas G,Zagouri F,Tsolaki E,Gogas H,Koutras A,Pentheroudakis G,Timotheadou E,Pervana S,Goussia A,Petraki K,Sotiropoulou M,Koletsa T,Razis E,Kosmidis P,Aravantinos G,Papadimitriou C

    更新日期：2018-02-01 00:00:00

  • Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials.

    abstract：:A pilot chemoprevention study from the Royal Marsden Hospital in the United Kingdom demonstrated that tamoxifen could be administered safely to healthy women. This led to the establishment of multicenter trials, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 and Italian National Cancer I...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.008

    authors： Ross PJ,Powles TJ

    更新日期：2001-04-01 00:00:00

  • Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.

    abstract：BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2010.n.008

    authors： Barcenas CH,Wells J,Chong D,French J,Looney SW,Samuel TA

    更新日期：2010-02-01 00:00:00

  • Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

    abstract：:Breast cancer is the most common type of cancer among women and the second leading cause of cancer death in the United States. Metastatic breast cancer is considered incurable, and treatment is aimed at palliating symptoms, achieving remission, and prolonging survival. Treatment options for metastatic disease vary bas...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2011.07.001

    authors： Sachdev JC,Jahanzeb M

    更新日期：2012-02-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.04.008

    authors： Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期：2015-12-01 00:00:00

  • Will we need lymph node dissection at all in the future?

    abstract：:Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2002.n.034

    authors： Bourez RL,Rutgers EJ,Van De Velde CJ

    更新日期：2002-12-01 00:00:00

  • Comprehensive review of sentinel lymphadenectomy in breast cancer.

    abstract：:Sentinel lymph node dissection (SLND) is a minimally invasive technique to stage axillary lymph nodes in breast cancer. The complications associated with SLND are minimal, especially when compared to routine axillary lymph node dissection (ALND), and it can be performed with an overall identification rate of greater t...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2000.n.010

    authors： Kelemen PR

    更新日期：2000-07-01 00:00:00

  • Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.

    abstract：BACKGROUND:Elderly patients form a large proportion of patients with breast cancer but are underrepresented in clinical trials. We examined whether elderly patients experience more toxicity than younger patients within breast cancer clinical trials. MATERIALS AND METHODS:All breast cancer trials open from 1999 to 2012...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.002

    authors： Mariano C,Francl M,Pope J,Wong L,Lim HJ,Lohrisch C

    更新日期：2015-02-01 00:00:00

  • Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

    abstract：:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disea...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/cbc.2003.n.017

    authors： Fountzilas G,Razis E,Tsavdaridis D,Karina M,Labropoulos S,Christodoulou C,Mavroudis D,Gogas H,Georgoulias V,Skarlos D

    更新日期：2003-06-01 00:00:00

  • Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis.

    abstract：BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.11.006

    authors： Giatromanolaki A,Sivridis E,Kalamida D,Koukourakis MI

    更新日期：2017-06-01 00:00:00

  • Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.

    abstract：BACKGROUND:To date, there have been no analyses to assess factors that influence post-mastectomy radiation therapy (PMRT) utilization in invasive lobular carcinoma (ILC) or to quantify the benefit of PMRT in ILC as compared with invasive ductal carcinoma (IDC). We compared histology-specific utilization of PMRT by tumo...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.02.001

    authors： Stecklein SR,Shen X,Mitchell MP

    更新日期：2016-08-01 00:00:00

  • The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.

    abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.05.007

    authors： Escott CE,Zaenger D,Switchencko JM,Lin JY,Abugideiri M,Arciero CA,Pfister NT,Xu KM,Meisel JL,Subhedar P,Torres M,Curran WJ,Patel PR

    更新日期：2020-12-01 00:00:00

  • Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

    abstract：:Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...

    journal_title：Clinical breast cancer

    pub_type： 临床试验,杂志文章

    doi：10.3816/cbc.2002.s.004

    authors： O'Shaughnessy J,Vukelja SJ,Marsland T,Kimmel G,Ratnam S,Pippen J

    更新日期：2002-05-01 00:00:00

  • Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.

    abstract：BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.04.013

    authors： Rayson D,Payne JI,Michael JCR,Tsuruda KM,Abdolell M,Barnes PJ

    更新日期：2018-10-01 00:00:00

  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

    abstract：PURPOSE:This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer (MBC). PATIENTS AND METHODS:We treated 32 patients who had measurable MBC t...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CBC.2010.n.036

    authors： Conlin AK,Seidman AD,Bach A,Lake D,Dickler M,D'Andrea G,Traina T,Danso M,Brufsky AM,Saleh M,Clawson A,Hudis CA

    更新日期：2010-08-01 00:00:00

  • Aromatase inhibitors for the treatment and prevention of breast cancer.

    abstract：:In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2005.n.006

    authors： Kalidas M,Brown P

    更新日期：2005-04-01 00:00:00

  • Added Value of Breast MRI for Preoperative Diagnosis of Ductal Carcinoma In Situ: Diagnostic Performance on 362 Patients.

    abstract：INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.12.007

    authors： Petrillo A,Fusco R,Petrillo M,Triunfo F,Filice S,Vallone P,Setola SV,Rubulotta M,Di Bonito M,Rinaldo M,D'Aiuto M,Brunetti A

    更新日期：2017-06-01 00:00:00

  • Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.

    abstract：:Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.n.029

    authors： Robson M

    更新日期：2004-10-01 00:00:00

  • Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.

    abstract：BACKGROUND:This study aimed to investigate the use of nonpegylated liposomal doxorubicin (NPLD) in the management of metastatic breast cancer (MBC) within routine UK clinical practice and to assess its efficacy and tolerability. PATIENTS AND METHODS:All patients that received NPLD for MBC at 5 institutions were identi...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2013.10.011

    authors： Palmieri C,Misra V,Januszewski A,Yosef H,Ashford R,Keary I,Davidson N

    更新日期：2014-04-01 00:00:00

  • Dietary Habits and Physical Activity are Associated With the Risk of Breast Cancer Among Young Iranian Women: A Case-control Study on 1010 Premenopausal Women.

    abstract：BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.10.011

    authors： Fararouei M,Iqbal A,Rezaian S,Gheibi Z,Dianatinasab A,Shakarami S,Dianatinasab M

    更新日期：2019-02-01 00:00:00

  • Conservative Management of Positive Axilla After Neoadjuvant Systemic Therapy-The Need for, and Review of, Techniques Used for Lymph Node Localization.

    abstract：:Involvement of axillary lymph nodes is an important prognostic factor in relationship to the management of breast cancer. However, the use of neoadjuvant systemic therapy is widespread in the treatment of positive axilla and such treatment leads to downstaging of axillary disease. Hence, the role of targeted axillary ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.06.001

    authors： Green M,Neamonitou F,Vidya R

    更新日期：2018-10-01 00:00:00

  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

    abstract：INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.11.018

    authors： Hull LE,Lynch JA,Berse BB,DuVall SL,Chun DS,Venne VL,Efimova OV,Icardi MS,Kelley MJ

    更新日期：2018-04-01 00:00:00

  • Isolated Contralateral Axillary Lymph Node Involvement in Breast Cancer Represents a Locally Advanced Disease Not Distant Metastases.

    abstract：BACKGROUND:Breast cancer metastases to an ipsilateral supraclavicular lymph node is assigned a N3 status in the TNM system and thus classified as stage III disease in the American Joint Commission on Cancer staging manual. Breast cancer metastatic to contralateral axillary lymph node (CAM) without metastases to any oth...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.10.019

    authors： Chkheidze R,Sanders MAG,Haley B,Leitch AM,Sahoo S

    更新日期：2018-08-01 00:00:00

  • A Survey of Breast Pathologists' Practice in Staging Multiple Foci of Invasive Carcinoma.

    abstract：BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.11.018

    authors： Wu JM,Turashvili G

    更新日期：2020-12-05 00:00:00

  • Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.

    abstract：PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2013.10.013

    authors： Luu T,Frankel P,Chung C,Chow W,Mortimer J,Hurria A,Somlo G

    更新日期：2014-04-01 00:00:00

  • An independent assessment of the 7 nomograms for predicting the probability of additional axillary nodal metastases after positive sentinel lymph node biopsy in a cohort of British patients with breast cancer.

    abstract：INTRODUCTION:Axillary lymph node dissection (ALND) is currently the recommended procedure in patients with tumor-positive sentinel lymph node biopsy (SLNB). A significant proportion of patients with positive SLNs will not have any additional metastases in nonsentinel lymph nodes (NSLNs). Predictive nomograms could iden...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.02.006

    authors： Nadeem RM,Gudur LD,Saidan ZA

    更新日期：2014-08-01 00:00:00

  • Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

    abstract：:In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.01.001

    authors： Kittaneh M,Badve S,Caldera H,Coleman R,Goetz MP,Mahtani R,Mamounas E,Kalinsky K,Lower E,Pegram M,Press MF,Rugo HS,Schwartzberg L,Traina T,Vogel C

    更新日期：2020-06-01 00:00:00

  • Development and Validation of a Preoperative Scoring System to Distinguish Between Nonadvanced and Advanced Axillary Lymph Node Metastasis in Patients With Early-stage Breast Cancer.

    abstract：BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.11.008

    authors： Murata T,Watase C,Shiino S,Jimbo K,Iwamoto E,Yoshida M,Takayama S,Suto A

    更新日期：2020-11-17 00:00:00